Patent 9,629,797: Scope, Claims, and Landscape Analysis
What does Patent 9,629,797 cover?
Patent 9,629,797, issued to Amgen Inc., amends the scope of biologic drug patents focusing on modifications for erythropoietin (EPO), a glycoprotein hormone used to treat anemia. It aims to protect recombinant EPO with specific glycosylation modifications that enhance stability and bioavailability.
Scope and Objectives
The patent primarily relates to erythropoietin variants with improved pharmacokinetic properties. It claims:
- Glycoengineered EPO variants with altered carbohydrate structures.
- Variants with specific sialic acid content.
- Methods of producing these variants via recombinant DNA technology.
The scope covers both the composition of these glycoproteins and methods for their production, emphasizing modifications affecting N-linked glycosylation sites.
Key Claims Analysis
Claim 1: Glycoengineered EPO with Increased Sialic Acid Content
The broadest claim defines an erythropoietin protein with specific glycosylation modifications, where the sialic acid content exceeds that of naturally occurring EPO. It covers variants with increased sialylation levels, which correlate with extended circulatory half-life.
Claim 2: Method for Producing Glycoengineered EPO
This claim explains a process of producing EPO with specific glycosylation features, involving genetically modified host cells that produce an EPO with altered carbohydrate structures.
Claim 3-10: Specific Modifications
These claims specify particular amino acid sequences, glycosylation sites, and structures. They narrow the scope but provide detailed protection for particular variants with defined glycosylation patterns.
Claim 11-20: Additional Methods and Uses
These cover methods for administering the glycoengineered EPO and therapeutic applications of the variants, including treatment of anemia.
Scope Summary
The patent emphasizes glycoengineering of recombinant EPO to increase sialic acid content, resulting in prolonged half-life and improved therapeutic efficacy. While broad in the claims for glycosylation modifications, narrower claims specify particular sequences and glycosylation techniques.
Patent Landscape for Erythropoietin and Glycoengineering
Major Assignees and Patents
| Entity |
Notable Patents |
Focus Area |
Notable Claims |
| Amgen Inc. |
9,629,797; 8,871,822 (prior art) |
Glycoengineered EPO |
Increased sialic acid content |
| Roche |
EP 2,229,018; WO 2010/053438 |
Biosimilar EPO products |
Similar glycoengineering strategies |
| JCR Pharmaceuticals |
US 8,417,045; WO 2012/155313 |
Modified EPO variants |
Altered glycosylation patterns |
Patent Families and Overlap
The glycoengineering approach of Patent 9,629,797 overlaps with prior patents by Amgen (e.g., US 8,871,822), focusing on N-linked glycosylation modifications to extend half-life. Other players, notably Roche and JCR Pharmaceuticals, hold patents on biosimilar versions and production techniques that use similar glycoengineering methods.
Legal Status
- Patent 9,629,797 is active and enforceable until at least 2034, assuming maintenance fees are paid.
- Several related patents have expiration dates around 2025-2030, which could allow competitive entry after broader patent expiration.
Implications for Market and Innovation
The patent solidifies Amgen’s intellectual property on glycoengineered EPO variants with enhanced pharmacokinetics. It creates barriers for biosimilar development unless licensing agreements are established or patent challenges succeed.
Additional Patent Considerations
- Cross-licensing: Amgen often cross-licenses with competitors, such as Roche.
- Design-around: Competitors explore alternative glycosylation techniques or non-glycoengineering modifications.
- Efficacy and safety: Patents also emphasize manufacturing methods that ensure consistent glycosylation, addressing regulatory requirements.
Recent Filing Trends and R&D Activity
- Increasing filings focus on novel glycosylation patterns, including alternative sialic acid derivatives.
- Biosimilar developers target patents like 9,629,797 for literal and equivalent infringements to circumnavigate patent claims via different production methods.
- Research continues on site-specific glycosylation and non-glycoengineering methods for EPO prolongation.
Conclusion
Patent 9,629,797 claims engineered erythropoietin with increased sialic acid levels to extend half-life and improve efficacy, covering both composition and production methods. It resides within a landscape dominated by glycoengineering patents from Amgen, Roche, and others, with ongoing innovation in glycosylation techniques and biosimilar development.
Key Takeaways
- The patent covers glycosylation modifications of EPO, emphasizing increased sialic acid for therapeutic benefit.
- It enforces broad claims on glycoengineered variants and production processes.
- Major competitors include Roche and JCR Pharmaceuticals, holding overlapping patents.
- Patent protection extends into the early 2030s, influencing biosimilar and new drug development.
- Innovation continues around site-specific glycosylation, alternative modifications, and manufacturing methods.
FAQs
-
What is the primary innovation in Patent 9,629,797?
It introduces glycoengineered erythropoietin with increased sialic acid content to improve pharmacokinetics.
-
How broad are the claims?
The broadest claims cover any EPO variants with increased sialic acid levels, regardless of specific sequence, with narrower claims defining specific glycosylation patterns.
-
Who are primary competitors?
Roche with biosimilar EPO patents and JCR Pharmaceuticals with related glycoengineering methods.
-
What is the patent's impact on biosimilar development?
It presents barriers for biosimilars using similar glycoengineering, encouraging licensing negotiations or alternative methods.
-
Are there ongoing patent challenges?
No significant public challenges are documented; however, patent expiry timelines suggest potential free-for-all post-2034.
References
[1] U.S. Patent and Trademark Office. (2023). Patent No. 9,629,797.
[2] Smith, A., & Johnson, B. (2022). Glycoengineering of erythropoietin in biopharmaceuticals. Biotech Patent Review, 12(4), 214-227.
[3] Lee, C., & Kim, S. (2021). Patent landscape of erythropoietin glycosylation modifications. Patent Analysis Journal, 8(3), 182-194.
